Cantor Fitzgerald reissued their overweight rating on shares of Unity Biotechnology (NASDAQ:UBX) in a report released on Thursday, December 12th, BenzingaRatingsTable reports. The brokerage currently has a $20.00 price target on the stock.

A number of other equities research analysts have also recently weighed in on UBX. Zacks Investment Research upgraded Unity Biotechnology from a sell rating to a buy rating and set a $8.25 price target on the stock in a research note on Wednesday, December 11th. Mizuho restated a buy rating and issued a $33.00 price target on shares of Unity Biotechnology in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $18.81.

NASDAQ UBX opened at $7.10 on Thursday. The company has a market cap of $327.11 million, a PE ratio of -2.80 and a beta of 0.01. Unity Biotechnology has a 12 month low of $5.61 and a 12 month high of $16.87. The stock has a 50 day moving average of $7.38 and a 200-day moving average of $7.21.

Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.05). As a group, equities analysts predict that Unity Biotechnology will post -1.99 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of UBX. Tower Research Capital LLC TRC bought a new position in shares of Unity Biotechnology in the third quarter worth $45,000. Bank of Montreal Can boosted its stake in Unity Biotechnology by 164,400.0% in the second quarter. Bank of Montreal Can now owns 4,935 shares of the companys stock valued at $47,000 after buying an additional 4,932 shares in the last quarter. Aperio Group LLC acquired a new stake in Unity Biotechnology in the second quarter valued at about $50,000. Squarepoint Ops LLC acquired a new stake in Unity Biotechnology in the third quarter valued at about $82,000. Finally, Ellington Management Group LLC acquired a new stake in Unity Biotechnology in the second quarter valued at about $103,000. Institutional investors own 35.56% of the companys stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Recommended Story: What are the benefits of a balanced fund?

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
Unity Biotechnology (NASDAQ:UBX) Stock Rating Reaffirmed by Cantor Fitzgerald - Riverton Roll